PL2547205T3 - Nowe sposoby do celowania nowotworowych komórek macierzystych - Google Patents
Nowe sposoby do celowania nowotworowych komórek macierzystychInfo
- Publication number
- PL2547205T3 PL2547205T3 PL11757135.6T PL11757135T PL2547205T3 PL 2547205 T3 PL2547205 T3 PL 2547205T3 PL 11757135 T PL11757135 T PL 11757135T PL 2547205 T3 PL2547205 T3 PL 2547205T3
- Authority
- PL
- Poland
- Prior art keywords
- stem cells
- cancer stem
- novel methods
- targeting cancer
- targeting
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US32581410P | 2010-04-19 | 2010-04-19 | |
| PCT/US2011/029283 WO2011116399A1 (en) | 2010-03-19 | 2011-03-21 | Novel methods for targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2547205T3 true PL2547205T3 (pl) | 2024-07-08 |
Family
ID=47678420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11757135.6T PL2547205T3 (pl) | 2010-03-19 | 2011-03-21 | Nowe sposoby do celowania nowotworowych komórek macierzystych |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9730909B2 (pl) |
| EP (1) | EP2547205B1 (pl) |
| JP (1) | JP2013522326A (pl) |
| CN (1) | CN103025159A (pl) |
| AU (1) | AU2011227023B2 (pl) |
| BR (1) | BR112012023660B8 (pl) |
| CA (2) | CA2793527A1 (pl) |
| DK (1) | DK2547205T3 (pl) |
| ES (1) | ES2987670T3 (pl) |
| FI (1) | FI2547205T3 (pl) |
| HR (1) | HRP20240658T1 (pl) |
| LT (1) | LT2547205T (pl) |
| PL (1) | PL2547205T3 (pl) |
| RS (1) | RS65536B1 (pl) |
| RU (1) | RU2591823C2 (pl) |
| SI (1) | SI2547205T1 (pl) |
| SM (1) | SMT202400193T1 (pl) |
| WO (1) | WO2011116399A1 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736564A1 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| PT2547205T (pt) * | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Novos métodos para atingir células estaminais cancerígenas |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN109867647A (zh) | 2014-02-07 | 2019-06-11 | 北京强新生物科技有限公司 | 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐 |
| US10005752B2 (en) * | 2014-06-09 | 2018-06-26 | Kyoto Pharmaceutical Industries, Ltd. | Anticancer agent |
| JP2018511643A (ja) | 2015-04-17 | 2018-04-26 | ボストン バイオメディカル， インコーポレイテッド | 癌を治療するための方法 |
| BR112017022269A2 (pt) | 2015-04-17 | 2018-07-10 | Boston Biomedical Inc | métodos para tratar câncer |
| MX2017015618A (es) | 2015-06-03 | 2018-08-15 | Boston Biomedical Inc | Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer. |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| EP3405189A1 (en) | 2016-01-20 | 2018-11-28 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018005444A2 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
| SG11202008686TA (en) * | 2018-03-08 | 2020-10-29 | Exxonmobil Res & Eng Co | Spirocentric compounds and polymers thereof |
| EP3865130A4 (en) | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER |
| CN111825644B (zh) * | 2019-04-18 | 2023-07-28 | 中国医学科学院药物研究所 | 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途 |
| CN117350965A (zh) * | 2023-10-07 | 2024-01-05 | 中国原子能科学研究院 | 对象内放射性微球的指标预估装置 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0402192A1 (fr) | 1989-05-31 | 1990-12-12 | BODET, Jean Augustin | Article en carton ou matière analogue et procédé de fabrication |
| JPH04139177A (ja) | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | フラルベンゾキノン誘導体及びその製造方法並びに制癌剤 |
| JPH1121284A (ja) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | フラノナフトキノン誘導体及びこれを含有する医薬 |
| US6174913B1 (en) | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
| CA2361621A1 (en) | 1999-01-27 | 2000-08-03 | Richard Jove | Inhibition of stat3 signal transduction for human cancer therapy |
| US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
| CN1166618C (zh) | 1999-08-02 | 2004-09-15 | 霍夫曼-拉罗奇有限公司 | 新型选择性视黄醛激动剂 |
| JP2001097860A (ja) | 1999-09-29 | 2001-04-10 | Japan Science & Technology Corp | 抗薬剤耐性菌剤と抗クラミジア剤 |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| AU2002307217A1 (en) | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| GB0117696D0 (en) * | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
| WO2003045357A1 (en) | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
| BR0214571A (pt) * | 2001-11-29 | 2006-05-30 | Therakos Inc | métodos para pré-tratar um indivìduo com fotoférese extracorporal e/ou células apoptóticas |
| PT1344533E (pt) | 2002-03-15 | 2007-01-31 | Natimmune As | Composições farmacêuticas compreendendo lectina de ligação a manose |
| WO2004026253A2 (en) | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| IS6633A (is) | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US20050049207A1 (en) | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
| WO2005033048A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Wnt pathway antagonists |
| KR101218633B1 (ko) | 2003-12-11 | 2013-01-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 세포 증식 질환 치료용 화합물 |
| CA2563305A1 (en) | 2004-04-09 | 2005-11-24 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
| JP2004224802A (ja) | 2004-04-21 | 2004-08-12 | Japan Science & Technology Agency | 抗菌剤 |
| MX2007006204A (es) | 2004-11-24 | 2007-06-20 | Novartis Ag | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. |
| US20060247318A1 (en) | 2005-02-25 | 2006-11-02 | Hui Song | Small molecule inhibitors of STAT3 and the uses thereof |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| CN101142202A (zh) * | 2005-03-16 | 2008-03-12 | 太日保日本株式会社 | 抗癌化合物及其中间体和生产方法 |
| JP2006290871A (ja) | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
| US20060252073A1 (en) | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| US20070243192A1 (en) | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
| EP2514742B1 (en) | 2006-03-31 | 2014-12-31 | The Board of Regents of The University of Texas System | Orally bioavailable cafeic acid related anticancer drugs |
| US20070238770A1 (en) | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
| JP4077863B1 (ja) | 2007-05-31 | 2008-04-23 | タヒボジャパン株式会社 | 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法 |
| CA2736564A1 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| US20100298402A1 (en) | 2007-11-06 | 2010-11-25 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
| PT2547205T (pt) * | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Novos métodos para atingir células estaminais cancerígenas |
-
2011
- 2011-03-21 PL PL11757135.6T patent/PL2547205T3/pl unknown
- 2011-03-21 CA CA2793527A patent/CA2793527A1/en not_active Abandoned
- 2011-03-21 RU RU2012144420/15A patent/RU2591823C2/ru active
- 2011-03-21 SI SI201132110T patent/SI2547205T1/sl unknown
- 2011-03-21 FI FIEP11757135.6T patent/FI2547205T3/fi active
- 2011-03-21 EP EP11757135.6A patent/EP2547205B1/en active Active
- 2011-03-21 BR BR112012023660A patent/BR112012023660B8/pt active IP Right Grant
- 2011-03-21 DK DK11757135.6T patent/DK2547205T3/da active
- 2011-03-21 CN CN2011800233152A patent/CN103025159A/zh active Pending
- 2011-03-21 JP JP2013500247A patent/JP2013522326A/ja active Pending
- 2011-03-21 RS RS20240574A patent/RS65536B1/sr unknown
- 2011-03-21 ES ES11757135T patent/ES2987670T3/es active Active
- 2011-03-21 AU AU2011227023A patent/AU2011227023B2/en active Active
- 2011-03-21 CA CA2946890A patent/CA2946890A1/en not_active Abandoned
- 2011-03-21 WO PCT/US2011/029283 patent/WO2011116399A1/en active Application Filing
- 2011-03-21 LT LTEPPCT/US2011/029283T patent/LT2547205T/lt unknown
- 2011-03-21 HR HRP20240658TT patent/HRP20240658T1/hr unknown
- 2011-03-21 SM SM20240193T patent/SMT202400193T1/it unknown
- 2011-03-21 US US13/634,694 patent/US9730909B2/en not_active Expired - Fee Related
-
2017
- 2017-07-05 US US15/642,105 patent/US20170319537A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2793527A1 (en) | 2011-09-22 |
| CN103025159A (zh) | 2013-04-03 |
| FI2547205T3 (fi) | 2024-05-27 |
| HRP20240658T1 (hr) | 2024-08-16 |
| US20170319537A1 (en) | 2017-11-09 |
| EP2547205B1 (en) | 2024-03-20 |
| ES2987670T3 (es) | 2024-11-15 |
| AU2011227023A1 (en) | 2012-09-27 |
| US9730909B2 (en) | 2017-08-15 |
| EP2547205A4 (en) | 2013-08-14 |
| AU2011227023B2 (en) | 2015-05-28 |
| JP2013522326A (ja) | 2013-06-13 |
| RS65536B1 (sr) | 2024-06-28 |
| RU2012144420A (ru) | 2014-04-27 |
| SMT202400193T1 (it) | 2024-07-09 |
| BR112012023660A2 (pt) | 2015-09-15 |
| DK2547205T3 (da) | 2024-05-27 |
| LT2547205T (lt) | 2024-06-10 |
| BR112012023660B1 (pt) | 2021-05-18 |
| US20130028944A1 (en) | 2013-01-31 |
| CA2946890A1 (en) | 2011-09-22 |
| SI2547205T1 (sl) | 2024-08-30 |
| BR112012023660B8 (pt) | 2021-05-25 |
| WO2011116399A1 (en) | 2011-09-22 |
| EP2547205A1 (en) | 2013-01-23 |
| RU2591823C2 (ru) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2547205T3 (pl) | Nowe sposoby do celowania nowotworowych komórek macierzystych | |
| IL220756A0 (en) | Herbicide-tolerant plants | |
| EP2749641A4 (en) | CANCER STEM CELLS ISOLATION | |
| PT2547205T (pt) | Novos métodos para atingir células estaminais cancerígenas | |
| PT2785834T (pt) | Composição de células estaminais melhorada | |
| EP2601290A4 (en) | SOMATIC STEM CELLS | |
| EP2772268B8 (en) | Cancer stem cell-specific molecule | |
| GB201016139D0 (en) | Cancer phosholipidome | |
| IL255309B (en) | Reprogramming of cancer cells | |
| RS57062B1 (sr) | Biljke tolerantne na herbicide | |
| EP2760996A4 (en) | SOMATIC STEM CELLS | |
| WO2011116344A9 (en) | Targeting cancer stem cells | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| PT2831110T (pt) | Terapia anti-emp2 reduz as células-tronco do cancro | |
| RS62406B1 (sr) | Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera | |
| PL2568796T3 (pl) | Półzawieszany pług obracalny | |
| WO2012106368A9 (en) | Methods for inhibiting prostate cancer | |
| HK40106589A (en) | Cancer stem cell targeted cancer vaccines | |
| SG196714A1 (en) | Cancer stem cell inhibition | |
| GB201021372D0 (en) | CD24 cancer stem cell | |
| ZA201205860B (en) | Herbicide-tolerant plants | |
| AU2011900981A0 (en) | Inhibition of cancer stem cells | |
| GB201012495D0 (en) | Targeted differntiation of stem cells | |
| HUE044196T2 (hu) | Sejtterápia | |
| EP2598166A4 (en) | CELLS WITHOUT CMH |